IBDEI0HW ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8699,1,4,0)
 ;;=4^365.72
 ;;^UTILITY(U,$J,358.3,8699,2)
 ;;=^340514
 ;;^UTILITY(U,$J,358.3,8700,0)
 ;;=365.73^^58^613^28
 ;;^UTILITY(U,$J,358.3,8700,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8700,1,3,0)
 ;;=3^Glaucoma Severe Stage
 ;;^UTILITY(U,$J,358.3,8700,1,4,0)
 ;;=4^365.73
 ;;^UTILITY(U,$J,358.3,8700,2)
 ;;=^340515
 ;;^UTILITY(U,$J,358.3,8701,0)
 ;;=362.51^^58^613^1
 ;;^UTILITY(U,$J,358.3,8701,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8701,1,3,0)
 ;;=3^AMD,Dry
 ;;^UTILITY(U,$J,358.3,8701,1,4,0)
 ;;=4^362.51
 ;;^UTILITY(U,$J,358.3,8701,2)
 ;;=^268636
 ;;^UTILITY(U,$J,358.3,8702,0)
 ;;=362.52^^58^613^2
 ;;^UTILITY(U,$J,358.3,8702,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8702,1,3,0)
 ;;=3^AMD,Wet/Exudative
 ;;^UTILITY(U,$J,358.3,8702,1,4,0)
 ;;=4^362.52
 ;;^UTILITY(U,$J,358.3,8702,2)
 ;;=^268637
 ;;^UTILITY(U,$J,358.3,8703,0)
 ;;=362.04^^58^613^14
 ;;^UTILITY(U,$J,358.3,8703,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8703,1,3,0)
 ;;=3^DM Mild NPDR
 ;;^UTILITY(U,$J,358.3,8703,1,4,0)
 ;;=4^362.04
 ;;^UTILITY(U,$J,358.3,8703,2)
 ;;=^332787
 ;;^UTILITY(U,$J,358.3,8704,0)
 ;;=362.05^^58^613^15
 ;;^UTILITY(U,$J,358.3,8704,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8704,1,3,0)
 ;;=3^DM Moderate NPDR
 ;;^UTILITY(U,$J,358.3,8704,1,4,0)
 ;;=4^362.05
 ;;^UTILITY(U,$J,358.3,8704,2)
 ;;=^332788
 ;;^UTILITY(U,$J,358.3,8705,0)
 ;;=362.06^^58^613^17
 ;;^UTILITY(U,$J,358.3,8705,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8705,1,3,0)
 ;;=3^DM Severe NPDR
 ;;^UTILITY(U,$J,358.3,8705,1,4,0)
 ;;=4^362.06
 ;;^UTILITY(U,$J,358.3,8705,2)
 ;;=^332789
 ;;^UTILITY(U,$J,358.3,8706,0)
 ;;=362.02^^58^613^16
 ;;^UTILITY(U,$J,358.3,8706,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8706,1,3,0)
 ;;=3^DM PDR
 ;;^UTILITY(U,$J,358.3,8706,1,4,0)
 ;;=4^362.02
 ;;^UTILITY(U,$J,358.3,8706,2)
 ;;=^268610
 ;;^UTILITY(U,$J,358.3,8707,0)
 ;;=379.39^^58^613^45
 ;;^UTILITY(U,$J,358.3,8707,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8707,1,3,0)
 ;;=3^Pseudophakia
 ;;^UTILITY(U,$J,358.3,8707,1,4,0)
 ;;=4^379.39
 ;;^UTILITY(U,$J,358.3,8707,2)
 ;;=^87515
 ;;^UTILITY(U,$J,358.3,8708,0)
 ;;=367.9^^58^613^18
 ;;^UTILITY(U,$J,358.3,8708,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8708,1,3,0)
 ;;=3^Disorder of Refraction
 ;;^UTILITY(U,$J,358.3,8708,1,4,0)
 ;;=4^367.9
 ;;^UTILITY(U,$J,358.3,8708,2)
 ;;=^35634
 ;;^UTILITY(U,$J,358.3,8709,0)
 ;;=373.2^^58^613^35
 ;;^UTILITY(U,$J,358.3,8709,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8709,1,3,0)
 ;;=3^Meibomianitis
 ;;^UTILITY(U,$J,358.3,8709,1,4,0)
 ;;=4^373.2
 ;;^UTILITY(U,$J,358.3,8709,2)
 ;;=^22156
 ;;^UTILITY(U,$J,358.3,8710,0)
 ;;=V58.69^^58^613^33
 ;;^UTILITY(U,$J,358.3,8710,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8710,1,3,0)
 ;;=3^Long Term Use of Medication
 ;;^UTILITY(U,$J,358.3,8710,1,4,0)
 ;;=4^V58.69
 ;;^UTILITY(U,$J,358.3,8710,2)
 ;;=^303460
 ;;^UTILITY(U,$J,358.3,8711,0)
 ;;=379.24^^58^613^51
 ;;^UTILITY(U,$J,358.3,8711,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8711,1,3,0)
 ;;=3^Vitreous Floaters
 ;;^UTILITY(U,$J,358.3,8711,1,4,0)
 ;;=4^379.24
 ;;^UTILITY(U,$J,358.3,8711,2)
 ;;=^88242
 ;;^UTILITY(U,$J,358.3,8712,0)
 ;;=V80.2^^58^613^47
 ;;^UTILITY(U,$J,358.3,8712,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8712,1,3,0)
 ;;=3^Screening for Eye Condition
 ;;^UTILITY(U,$J,358.3,8712,1,4,0)
 ;;=4^V80.2
 ;;^UTILITY(U,$J,358.3,8712,2)
 ;;=^295685
 ;;^UTILITY(U,$J,358.3,8713,0)
 ;;=V70.5^^58^613^48
 ;;^UTILITY(U,$J,358.3,8713,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8713,1,3,0)
 ;;=3^Screening,Occupational
 ;;^UTILITY(U,$J,358.3,8713,1,4,0)
 ;;=4^V70.5
